Clinical Trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn which dose of study drug IBIO-600 has the right balance of safety, tolerability and impact on body composition in overweight and obese adult participants.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-30
Trial Details
NCT Number NCT07487376
Lead Sponsor iBio, Inc.
Conditions Overweight , Obesity
Enrollment 32 participants
Start Date 2026-05-24
Primary Completion 2027-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-05-29